Literature DB >> 27684565

Expansion of the GLE1-associated arthrogryposis multiplex congenita clinical spectrum.

C Smith1, J S Parboosingh1,2, K M Boycott3, C G Bönnemann4, J K Mah2,5, R E Lamont1,2, A Micheil Innes1,2, F P Bernier1,2.   

Abstract

Mutations in GLE1 cause two recessive subtypes of arthrogryposis multiplex congenita (AMC), a condition characterized by joint contractures at birth, and all previously reported patients died in the perinatal period. GLE1 related AMC has been almost exclusively reported in the Finnish population and is caused by a relatively common pathogenic splicing mutation in that population. Here, we report two non-Finnish brothers with novel compound heterozygous splicing mutations in GLE1, one of whom has survived to 12 years of age. We also demonstrate low levels of residual wild type transcript in fibroblasts from the surviving brother, suggesting that this residual wild-type transcript may contribute to the relatively longer-term survival in this family. We provide a detailed clinical report on the surviving patient, providing the first insight into the natural history of this rare neuromuscular disease. We also suggest that lethal congenital contracture syndrome 1 (LCCS1) and lethal arthrogryposis with anterior horn disease (LAAHD), the two AMC subtypes related to GLE1, do not have sufficient clinical or molecular differentiation to be considered allelic disorders. Rather, GLE1 mutations cause a variable spectrum of AMC severity including a non-lethal variant described herein.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  RNA metabolism; exome; infantile SMA; mRNA export; motor neuron disease; spinal muscular atrophy

Mesh:

Substances:

Year:  2017        PMID: 27684565     DOI: 10.1111/cge.12876

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  5 in total

1.  Pathogenic variants in nucleoporin TPR (translocated promoter region, nuclear basket protein) cause severe intellectual disability in humans.

Authors:  Nicole J Van Bergen; Katrina M Bell; Kirsty Carey; Russell Gear; Sean Massey; Edward K Murrell; Lyndon Gallacher; Kate Pope; Paul J Lockhart; Andrew Kornberg; Lynn Pais; Marzena Walkiewicz; Cas Simons; Vihandha O Wickramasinghe; Susan M White; John Christodoulou
Journal:  Hum Mol Genet       Date:  2022-02-03       Impact factor: 5.121

2.  Survival beyond the perinatal period expands the phenotypes caused by mutations in GLE1.

Authors:  Edith Said; Jessica X Chong; Maja Hempel; Jonas Denecke; Paul Soler; Tim Strom; Deborah A Nickerson; Christian Kubisch; Michael J Bamshad; Davor Lessel
Journal:  Am J Med Genet A       Date:  2017-09-08       Impact factor: 2.802

Review 3.  Pena-Shokeir syndrome: current management strategies and palliative care.

Authors:  Sumaiya Adam; Melantha Coetzee; Engela Magdalena Honey
Journal:  Appl Clin Genet       Date:  2018-10-25

4.  The importance of managing the patient and not the gene: expanded phenotype of GLE1-associated arthrogryposis.

Authors:  Queenie K-G Tan; Allyn McConkie-Rosell; Jane Juusola; Kathryn E Gustafson; Carolyn E Pizoli; Anne F Buckley; Yong-Hui Jiang
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-11-21

5.  Extension of the phenotypic spectrum of GLE1-related disorders to a mild congenital form resembling congenital myopathy.

Authors:  Mathieu Cerino; Chloé Di Meglio; Francesca Albertini; Frédérique Audic; Florence Riccardi; Christophe Boulay; Nicole Philip; Marc Bartoli; Nicolas Lévy; Martin Krahn; Brigitte Chabrol
Journal:  Mol Genet Genomic Med       Date:  2020-06-14       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.